The Cost of Oncology Drugs: A Pharmacy Perspective, Part I
- PMID: 30766201
- PMCID: PMC6375405
The Cost of Oncology Drugs: A Pharmacy Perspective, Part I
Abstract
Even in the VA, the high cost of oncology medications are forcing health care providers to confront the economic impact of cancer care.
Conflict of interest statement
Author disclosures The author reports no actual or potential conflicts of interest with regard to this article.
References
-
- Centers for Medicare and Medicaid. National health expenditure projections 2014–2024 Table 01. Centers for Medicare and Medicaid Website. [Accessed January 11, 2016]. https://www.cms.gov/research-statistics-data-and-systems/statistics-tren.... Updated July 30, 2015.
-
- Bach PB. Limits of Medicare’s ability to control rising spending on cancer drugs. N Engl J Med. 2009;360(6):626–633. - PubMed
-
- Himmelstein DU, Thorne D, Warren E, Woolhandler S. Medical bankruptcy in the United States, 2007: results of a national study. Am J Med. 2009;122(8):741–746. - PubMed
-
- The Henry J. Kaiser Family Foundation. Prescription drug costs remain atop the public’s national health care agenda, well ahead of Affordable Care Act revisions and_repeal [press release] Kaiser Family Foundation Website. [Accessed January 11, 2016]. http://kff.org/health-costs/press-release/prescription-drug-costs-remain.... Published October 28, 2015.
LinkOut - more resources
Full Text Sources